Currently out of the existing stock ratings of David Risinger, 116 are a BUY (60.1%), 65 are a HOLD (33.68%), 12 are a SELL (6.22%).

David Risinger

Work Performance Price Targets & Ratings Chart

Analyst David Risinger works at LEERINK with a stock forecast success ratio of 71.62% fulfilled within 204.58 days on average.

David Risinger’s has documented 416 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AMGN, Amgen at 11-Oct-2023.

Wall Street Analyst David Risinger

Analyst best performing recommendations are on BHC (BAUSCH HEALTH COMPANIES).
The best stock recommendation documented was for ALKS (ALKERMES PLC) at 1/21/2016. The price target of $35 was fulfilled within 1 day with a profit of $1.31 (3.89%) receiving and performance score of 38.88.

Average potential price target upside

of $66.85 (22.16%) on VRTX (VERTEX PHARMACEUTICALS).
of $61.5 (8.28%) on REGN (REGENERON PHARMACEUTICALS).
of $29.4 (11.61%) on AMGN (AMGEN).

ABBV AbbVie AGN Allergan plc ALKS Alkermes Plc BHC Bausch Health Companies ELAN Elanco Animal Health ENDP Endo International PLC GILD Gilead Sciences HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC LLY Eli Lilly and Company MNK Mallinckrodt plc MYL Viatris PRGO Perrigo Company PLC TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis BMY Bristol-Myers Squibb Company JNJ Johnson & Johnson PFE Pfizer PAHC Phibro Animal Health ROIV Roivant Sciences Ltd VTRS Viatris HALO Halozyme Therapeutics MRK Merck mpany RDUS Schnitzer Steel Industries REGN Regeneron Pharmaceuticals TBPH Theravance Biopharma AMGN Amgen VRTX Vertex Pharmaceuticals AMRX Amneal Pharmaceuticals, . Common Stock ASRT Assertio Therapeutics CNTA Centessa Pharmaceuticals PLC ADR

Show more stocks

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Carter Gould (BARCLAYS)